Among the remaining 18 patients in the treatment group, 7 (38.89%) achieved abstinence, 6 (33.33%) exhibited decreased phosphatidylethanol (PETh) levels, and 4 (22.22%) had higher PETh levels compared to their pre-LIFT visit levels
In several RCTs, GLP-1RAs, when used alone or in combination with other hypoglycemic agents including metformin, sulfonylurea, DPP-4 inhibitor, thiazolidinedione, and sodium-glucose cotransporter 2 inhibitor, showed superior or non-inferior blood glucose lowering ability compared to insulin treatment [64,65]
Many candidates also experience persistent cravings, insulin resistance, or metabolic slowing
Contact us today, or use the chatbot on this page for an instant case evaluation
Monitoring your overall wellbeing is crucial
They will increase, or titrate, the dose until it is effective